{
    "paper_id": "PMC7163506",
    "metadata": {
        "title": "Innovative approach for improved rFVIII concentrate",
        "authors": [
            {
                "first": "Massimo",
                "middle": [],
                "last": "Morfini",
                "suffix": "",
                "email": null,
                "affiliation": {}
            }
        ]
    },
    "body_text": [
        {
            "text": "Previous experience with FVIII products pointed potential risks in the development of a new rFVIII concentrate such as immunogenicity (the ability to induce an immune response) and neoantigenicity (ability to bind a secreted or surface antibody) 18.",
            "cite_spans": [],
            "section": "Manufacturing processes linked to immunologic safety of rFVIII",
            "ref_spans": []
        },
        {
            "text": "The production of antibodies against recombinant proteins is influenced by several factors, including structural properties of the protein, formulation, presence of impurities, and the formation of aggregates 19, 20. A large and complex protein such as FVIII requires critical posttranslational additions, particularly sulphation and glycosylation 21. Not all mammalian expression systems may implement all of the changes necessary for proper structure and function of FVIII 21. The choice of a suited cellular environment provides opportunity to minimize inhibitor incidence at the clinical level. Chinese hamster ovary (CHO) cells are the most commonly used mammalian \u2018recombinant\u2019 cell clone for large\u2010scale production of rFVIII 22. Progress in CHO culture technology brought to a substantial optimization in protein production, including improvement in gene expression, culture process, and medium development 23.",
            "cite_spans": [],
            "section": "Manufacturing processes linked to immunologic safety of rFVIII",
            "ref_spans": []
        },
        {
            "text": "N8 protein, the native structure of Turoctocog alfa synthesized in these CHO cells, shows sulphation and glycosylation patterns superimposable to those of plasma\u2010derived FVIII 24.",
            "cite_spans": [],
            "section": "Manufacturing processes linked to immunologic safety of rFVIII",
            "ref_spans": []
        },
        {
            "text": "Analysis of Turoctocog alfa for the degree of sulphation demonstrated that the all six tyrosine sites of FVIII are sulphated: every site performs a peculiar role in functional or antigenic term 24, 25, 26.",
            "cite_spans": [],
            "section": "Manufacturing processes linked to immunologic safety of rFVIII",
            "ref_spans": []
        },
        {
            "text": "Turoctocog alfa glycosylation is mainly characterized by the presence of carbohydrate chains ubiquitous in human organism 21, 24 and by absence of non\u2010human glycan epitopes, critically expressed by different culture cells 27, 28. These non\u2010human epitopes carry potential to real implications for inhibitory issues 29, 30.",
            "cite_spans": [],
            "section": "Manufacturing processes linked to immunologic safety of rFVIII",
            "ref_spans": []
        },
        {
            "text": "Futhermore, the characterization of sulphation and glycosylation has been a critical step to assess improvement and consistency of the production process 24.",
            "cite_spans": [],
            "section": "Manufacturing processes linked to immunologic safety of rFVIII",
            "ref_spans": []
        },
        {
            "text": "Amelioration of culture media from non\u2010animal sources is ongoing, and it is important to ensure products of consistent quality and without the potential danger of contamination 31. Plasma\u2010derived concentrates, other than potential danger of contamination, concern about consistent quality, product performance, and reliability of supply 32 . There are over 1000 different components in serum, including proteins, peptides, hormones, enzymes, electrolytes, lipids, carbohydrates, vitamins, and other constituents 33. Development of serum\u2010free media must be formulated for each cell line 31. In fact, even different clones of the same CHO cell line may require specific cultivation process and environment 34.",
            "cite_spans": [],
            "section": "Manufacturing processes linked to immunologic safety of rFVIII",
            "ref_spans": []
        },
        {
            "text": "The manufacture of Turoctocog alfa does not require any human\u2010 and animal\u2010derived component 35. Turoctocog alfa is produced in CHO cells growing in a medium free of plasma\u2010derived ingredient: a low\u2010protein synthetic medium contains all necessary nutrients and elements, which are filtrated to eliminate contaminants 24.",
            "cite_spans": [],
            "section": "Manufacturing processes linked to immunologic safety of rFVIII",
            "ref_spans": []
        },
        {
            "text": "Moreover, no animal\u2010derived material has been used in the production of any raw material employed in the manufacturing process, including chromatography media, the affinity ligand and filters 24. Hence, technology of plasma and animal free\u2010production of Turoctcog alfa resolve the safety issues of pathogen transmission through serum. In addition, serum\u2010free technology avoids variability of proteins and low\u2010protein medium avoids high protein content exposure. Both elements may contribute to reduce the immunogenicity of rFVIII.",
            "cite_spans": [],
            "section": "Manufacturing processes linked to immunologic safety of rFVIII",
            "ref_spans": []
        },
        {
            "text": "Manufacturers of recombinant products have addressed the issue of emerging infectious agents by acting on two fronts: limit up to cancel the use of human plasma in all reagents used for cell culture, purification steps, stabilization, and storage buffers 36; at the same time, virus inactivation and removal measures are adopted.",
            "cite_spans": [],
            "section": "Current challenges of viral safety",
            "ref_spans": []
        },
        {
            "text": "In the preparation of plasma\u2010derived products, the solvent/detergent process is the most common virus inactivation technique used, because this process is vulnerable to enveloped viruses, from known hepatitis viruses (HBV, HCV) or HIV to recently emerging West Nile virus, Chikungunya virus, new influenza strains and severe acute respiratory syndrome coronavirus 37. Gamma irradiation sized of the target virus is a widely employed method for inactivation of non\u2010lipid\u2010coated viruses, such as parvoviruses, enteroviruses and circoviruses 38. However, a study involving 195 hemophiliacs treated for 5 yr with virally inactivated clotting factor concentrates identified a seroconversion incidence of 1.7%/yr for anti\u2010human parvovirus 4, a transmissible agent that is resistant to viral inactivation via solvent/detergent treatment and to some extent to heat and radiation too 39.",
            "cite_spans": [],
            "section": "Current challenges of viral safety",
            "ref_spans": []
        },
        {
            "text": "Thus it's necessary to implement further methods for the inactivation and removal of potentially contaminating viruses, including separation/purification techniques (such as ion exchange and immunoaffinity chromatography) and nanofiltration.",
            "cite_spans": [],
            "section": "Current challenges of viral safety",
            "ref_spans": []
        },
        {
            "text": "The problem of blood safety remains despite the improvement of viral inactivation methods and plasma\u2010derived products could always cause infectious concerns 40. The risk of contracting novel pathogens, some of which could be actually not detectable, is sustained by continuous emergence of new agents and new strains of existing agents: potential threats are not limited to viruses, but include bacterial, protozoan, and prion agents 41. Among more than 60 such agents, including HIV and hepatitis viruses, some have been identified as the highest\u2010priority agents for which a blood safety intervention should be considered. (Table 1).",
            "cite_spans": [],
            "section": "Current challenges of viral safety",
            "ref_spans": [
                {
                    "start": 631,
                    "end": 632,
                    "mention": "1",
                    "ref_id": "TABREF0"
                }
            ]
        },
        {
            "text": "Recombinant FVIII concentrates have provided improved safety for patients with hemophilia A as they significantly reduce the risk of transmission of blood\u2010borne infections. Nevertheless, human\u2010 or animal\u2010derived plasma proteins are still included at some step in the preparation of first or second generation of rFVIII products, thereby introducing the potential for transmission of human or animal pathogens 50.",
            "cite_spans": [],
            "section": "Current challenges of viral safety",
            "ref_spans": []
        },
        {
            "text": "Two examples can be briefly treated. Parvovirus B19 is a small, non\u2010enveloped virus that typically causes a benign flu\u2010like illness that occurs most frequently in childhood. The virus is resistant to current viral inactivation steps used in the manufacture of anti\u2010hemophilic factor concentrates. B19V transmission through these products has been documented also after nucleic acid test (NAT) screening of plasma pools has been implemented: children exposed to plasma\u2010derived products were 1.7 times more likely to have antibodies to B19V compared to those unexposed to blood products 46. One first generation recombinant FVIII product containing human serum albumin, added to stabilize rFVIII before lyophilization, was associated to a reliable seroconversion for parvovirus B19 36. Even though the study conducted by Centers of Disease Control and Prevention of Atlanta was limited to detect serumconversion, the poor reliability of plasma mini\u2010pool screening by NAT was revealed. Albumin was also the source of TT virus found out in the first generation rFVIII concentrates 49.",
            "cite_spans": [],
            "section": "Current challenges of viral safety",
            "ref_spans": []
        },
        {
            "text": "Prions are self\u2010replicating infectious proteins that cause currently untreatable and fatal neurodegenerative disorders 51. vCJD, the human form of bovine spongiform encephalopathy, is a prion\u2010associated disease with a lengthy incubation period of 5\u201315 yr. An unexpectedly high transmission rates by transfusion of 36% for BSE and 43% for scrapie, together with a short and consistent incubation periods in clinically positive recipients have been experimentally demonstrated, suggesting that infectivity titers in blood were substantial and that blood transfusion is a possible vehicle of transmission 44. It is recent the demonstration of abnormal prion protein in a spleen sample at postmortem examination of a United Kingdom elderly hemophilia patient who received coagulation factor concentrates obtained by a pool of donors including a subject incubating vCJD and who subsequently died from vCJD 42, 43. The outcomes of a recent published survey conducted in United Kingdom to establish the prevalence of subclinical infections with prions in normal population showed that 16 of 32441 archived appendix samples were positive for abnormal prion protein (PrP) 52. This prevalence of 0.49/1000 is definitively not trivial taking into account the size of plasma pools (20\u20133000 L derived from 50\u20137500 donors!) fractionated to produce clotting factor concentrates. Peripheral lymphoreticular infections seem to be a weak barrier against cross\u2010species transmission of prions 53.",
            "cite_spans": [],
            "section": "Current challenges of viral safety",
            "ref_spans": []
        },
        {
            "text": "Of note are the challenges which make these infective agents elusive to recognition by surveillance policies. Many emerging blood\u2010borne infectious agents are characterized by long\u2010lasting, silent carrier states in which the pathogen is present in the circulation without causing noticeable symptoms, but the same pathogen is highly infectious when contained in blood or plasma 41. These blood\u2010borne agents have in common the transmission by transfusion, the association with a clinically apparent or fatal disease, and the lack of an effective intervention. Moreover, the prevalence of subclinical diseases is not known, as well as the challenges in dealing with undefined risks requiring the implementation of surveillance and risk management measures. Pathogens with blood\u2010borne stages that are resistant to viral inactivation steps in the manufacturing process must be taken into particular consideration as potential threats.",
            "cite_spans": [],
            "section": "Current challenges of viral safety",
            "ref_spans": []
        },
        {
            "text": "Turoctocog alfa, a novel advanced category rFVIII produced without the addition of any human or animal plasma proteins, has been developed with the aim of providing the best possible margin of safety to hemophilia patients, because it eliminates the risk of blood\u2010borne infections during lifelong therapy 24.",
            "cite_spans": [],
            "section": "Current challenges of viral safety",
            "ref_spans": []
        },
        {
            "text": "Turoctocog alfa is purified through a series of steps, including an immunoaffinity chromatography process utilizing a recombinant monoclonal antibody produced by cells grown in a plasma\u2010free environment 24.",
            "cite_spans": [],
            "section": "Current challenges of viral safety",
            "ref_spans": []
        },
        {
            "text": "In any case, as Turoctocog alfa is never exposed to plasma, the risk of transmitting known and emerging blood\u2010borne pathogens is virtually eliminated.",
            "cite_spans": [],
            "section": "Current challenges of viral safety",
            "ref_spans": []
        },
        {
            "text": "The advanced techniques of purification utilized for the production of Turoctocog alfa result in a final product formulation which is devoid of both albumin and animal/human\u2010derived materials.",
            "cite_spans": [],
            "section": "Purification as method of infectious safety",
            "ref_spans": []
        },
        {
            "text": "A total of five steps are employed to remove host cells, medium components, chemicals used during purification, DNA, and proteins. The key purification step uses a non\u2010animal\u2010derived affinity ligand that is produced in the same CHO cell line used for Turoctocog alfa and is specific for FVIII 24.",
            "cite_spans": [],
            "section": "Purification as method of infectious safety",
            "ref_spans": []
        },
        {
            "text": "The manufacturing process used for purify Turoctocog alfa, including two additional steps other than the minimum regulatory requirement, is depicted in Table 2.",
            "cite_spans": [],
            "section": "Purification as method of infectious safety",
            "ref_spans": [
                {
                    "start": 158,
                    "end": 159,
                    "mention": "2",
                    "ref_id": "TABREF1"
                }
            ]
        },
        {
            "text": "\n1.Solvent\u2010detergent (SD) treatment is a standardized and well documented process in terms of the spectrum of potential pathogen reduction 54. In addition to inactivate potential viral contaminants, SD process is necessary for product concentration. SD treatment for Turoctocog alfa is conducted in respect to the physicochemical/biological characteristics of rFVIII. Nevertheless, adverse reactions to the final preparation are possible when this technique is used for viral inactivation 24. Therefore, an additional practical step such as chromatography is required to remove the solvent/detergent residual chemicals and their metabolites 24.2.Immunoaffinity chromatography is a process which isolates only full molecules of rFVIII, that is, with an intact heavy chain. This chromatographic process uses a recombinant version of the monoclonal F25 antibody directed against integral A2 domain of the heavy chain, which must include residue 740 of the amino acid sequence. The step excludes incomplete molecules, particularly those with a damage on heavy chain at its weak point position 720, which is easily inactivated by proteolysis. Recombinant monoclonal antibody directed against A2 domain is produced in the same cell line used for production of Turoctocog alfa and its manufacturing is realized avoiding any contact with other animal additives 24.\n",
            "cite_spans": [],
            "section": "Purification as method of infectious safety",
            "ref_spans": []
        },
        {
            "text": "The affinity step is highly specific for FVIII and has been shown to reliably remove essentially all host cell proteins 24.",
            "cite_spans": [],
            "section": "Purification as method of infectious safety",
            "ref_spans": []
        },
        {
            "text": "\n3.Ion\u2010exchange chromatography removes impurities generated by the producing cell line, using electrical charges to eliminate other impurities, thus obtaining a further purification step of the product. The resin used for the mixed mode capture chromatography step also binds FVIII through multiple interactions, providing an additional tool for the removal of impurities.\n",
            "cite_spans": [],
            "section": "Purification as method of infectious safety",
            "ref_spans": []
        },
        {
            "text": "Researchers optimized the parameters of the chromatographic process to obtain a highly purified rFVIII concentrate. The best support matrix of ion exchange was selected to obtain the highest purified product, in that all investigated contaminant proteins have been found to be below the detection limit (data on file, personal communication).",
            "cite_spans": [],
            "section": "Purification as method of infectious safety",
            "ref_spans": []
        },
        {
            "text": "\n4.Nanofiltration: a 20 nm pore size filter has been designed for removal of almost all viruses, included protein enveloped viruses like Parvovirus. Nanofiltration increases the clearance capacities for viruses via a membrane\u2010based ultrafiltration system 55. It has been implemented to assure a high virus safety level, especially for non\u2010enveloped viruses, thus complementing the profile of viral reduction treatments active against enveloped viruses such as SD process 56. Non\u2010enveloped viruses, resistant to SD treatment, are too small to be removed if the filter is larger than 30 mn 56. Nanofiltration consists in filtering protein solutions through membranes of a very small pore size under conditions that retain viruses by a mechanism based on size exclusion 55.\n",
            "cite_spans": [],
            "section": "Purification as method of infectious safety",
            "ref_spans": []
        },
        {
            "text": "Turoctocog alfa is purified using a 20\u2010nm pore size filter for nanofiltration. Such a size is tight enough to remove the smallest viruses as it corresponds to that of Parvovirus, which have been shown to be a model for virus clearance validation method and to be efficiently removed by the 20 nm filter 56, 57. Such technique refinements led to improve viral removal as established by large\u2010scale world wide experience 55.",
            "cite_spans": [],
            "section": "Purification as method of infectious safety",
            "ref_spans": []
        },
        {
            "text": "In the purification process of a rFVIII product, prion removal capacities of 3.8 logs and >5.2 logs have been demonstrated for the immunoaffinity step, resulting in a total clearance of >9 log 24. Also nanofiltration may remove prions and provides a possible safeguard against new infectious agents potentially entering the human plasma pool 55.",
            "cite_spans": [],
            "section": "Purification as method of infectious safety",
            "ref_spans": []
        },
        {
            "text": "Lastly, the technology of membrane nanofiltration process has the major advantage not only in protein\u2010virus separation, but also in protein purification, with a recover of more than 95% of protein activity because the absence of denaturing effect 55, 58.",
            "cite_spans": [],
            "section": "Purification as method of infectious safety",
            "ref_spans": []
        },
        {
            "text": "\n5.Gel filtration step provides the pure protein Turoctocog alfa, eliminating aggregated/agglutinated forms of protein 24. A high capacity gel filtration system was developed with the purpose of isolating rFVIII in high yields. After implementation of gel filtration, a rFVIII\u2010containing fraction was collected containing exclusively FVIII and filtration was used to monitor the bioactivity and purity of the chromatographic product 24, 35.\n",
            "cite_spans": [],
            "section": "Purification as method of infectious safety",
            "ref_spans": []
        },
        {
            "text": "In summary, two dedicated virus clearance steps, S/D treatment and nanofiltration through a 20\u2010nm pore size filter, are included to ensure inactivation/removal of potentially present enveloped and non\u2010enveloped viruses. Indeed, in the purification process for Turoctocog alfa, the nanofiltration and the immunoaffinity step do contribute to prion reduction as well.",
            "cite_spans": [],
            "section": "Purification as method of infectious safety",
            "ref_spans": []
        },
        {
            "text": "Recombinant FVIII products are now classified into three generations based on the degree of elimination of plasma and albumin from production and/or formulation steps. First generation products use plasma and/or albumin during both the cell culture process and the final formulation steps, while second generation products use serum proteins during the cell culture process only. Plasma\u2010free recombinant proteins are classified as third generation products 59.",
            "cite_spans": [],
            "section": "Clinical evidence of safety",
            "ref_spans": []
        },
        {
            "text": "Many physicians' organizations in Commonwealth and other developed countries (Denmark, Canada, Japan) encourage switching to recombinant products as a standard for the treatment of hemophilia A, and both FDA and EMA have prompted drug and device manufacturers to find alternatives to the use of human and animal raw materials and additives whenever possible.",
            "cite_spans": [],
            "section": "Clinical evidence of safety",
            "ref_spans": []
        },
        {
            "text": "Together with viral safety, the main concern in the development of Turoctocog alfa was the attempt to reduce the formation of inhibitors to FVIII 18. The primary objective of the two GuardianTM phase 3 studies was therefore to evaluate the safety of Turoctocog alfa in terms of incidence of inhibitors 60, 61. Adult patients (n = 150) were exposed to Turoctocog alfa for a mean of 85 d (ranging from 11 to 172 exposure days) while young patients (n = 60) for a mean of 60 exposure days (range 20\u2013104 d) 60, 61. No patient developed inhibitors during both trials 60, 61. One adult patient was excluded from analysis because had a pretrial\u2010positive inhibitor test (1BU). Interestingly, this patient received 13 doses of Turoctocog alfa with no occurrence of inhibitors 60.",
            "cite_spans": [],
            "section": "Clinical evidence of safety",
            "ref_spans": []
        },
        {
            "text": "In a phase 2 study, the observations of 22 patients immediately after the first dose of Turoctocog alfa showed no signs of early inhibitor development. For instance, no inhibitor formation was reported in the 72\u2010h period after administration of a single dose of Turoctocog alfa (50 IU/kg) 18.",
            "cite_spans": [],
            "section": "Clinical evidence of safety",
            "ref_spans": []
        },
        {
            "text": "Regarding adverse events other than infection and inhibitor development in the Guardian\u2122 studies 60, 61, six non\u2010serious events (hypertension, sinus tachycardia, and insomnia in a 27\u2010yr\u2010old patient, increase of hepatic enzymes in a 37\u2010yr\u2010old patient, and contusion for incorrect dose administration in one pediatric patient) were evaluated as possibly or probably related to Turoctocog alfa by investigators 60, 61.",
            "cite_spans": [],
            "section": "Clinical evidence of safety",
            "ref_spans": []
        },
        {
            "text": "Overall, treatment with Turoctocog alfa was safe, with none \u2018infectious concern\u2019 60, 61.",
            "cite_spans": [],
            "section": "Clinical evidence of safety",
            "ref_spans": []
        },
        {
            "text": "Several new bioengineering technologies are now applied to FVIII to improve the quality of treatment of hemophilia patients. For example, a variety of approaches are under evaluation to increase the half\u2010life of FVIII thus reducing administration frequency. Addition of polyethylene glycol (PEG) and fusion proteins technologies are the most advanced in preclinical and clinical development 62.",
            "cite_spans": [],
            "section": "Turoctocog alfa and new rFVIII products",
            "ref_spans": []
        },
        {
            "text": "The structure of Turoctocog alfa, N8 protein, is so similar to native FVIII to be incorporated in a glycopegylated FVIII (N8\u2010GP) to increase plasma half\u2010life of FVIII 59. Indeed, a novel site\u2010specific PEGylation attaches a 40\u2010kDa PEG to a unique O\u2010glycan in the N8\u2010glycoprotein (N8\u2010GP) 63. When activated by thrombin, the residual part of the B\u2010domain containing the PEGylation is cleaved off, generating active FVIIIa that is similar in structure to native FVIIIa 63.",
            "cite_spans": [],
            "section": "Turoctocog alfa and new rFVIII products",
            "ref_spans": []
        },
        {
            "text": "The N8\u2010GP pharmacokinetic parameters were estimated in different animal models. In hemophilia A dogs, mice, rabbits, and monkeys, a nearly twofold prolongation of half\u2010life was demonstrated 63, 64. In a phase I clinical trial, N8\u2010GP demonstrated a significant increase of plasma half\u2010life. Twenty\u2010six patients received one dose of their previous FVIII product followed by the same, single dose of the N8\u2010GP 65. The mean terminal half\u2010life of N8\u2010GP was 19.0 h (range, 11.6\u201327.3), 1.6\u2010fold longer than that of the patients' previous products. The estimated time from dosing of 50 U/kg N8\u2010GP to a plasma activity of 1% was 6.5 d (range, 3.6\u20137.9) 65. A single dose of up to 75 U/kg N8\u2010GP was well tolerated in patients with hemophilia A, with no safety concerns 65.",
            "cite_spans": [],
            "section": "Turoctocog alfa and new rFVIII products",
            "ref_spans": []
        },
        {
            "text": "Taken together, clinical data show that Turoctocog alfa serves as an optimal tool for a long\u2010acting future FVIII product.",
            "cite_spans": [],
            "section": "Turoctocog alfa and new rFVIII products",
            "ref_spans": []
        },
        {
            "text": "The rationale for producing rFVIII is ultimately the reduction of immunogenic and infectious challenges to patients. For Turoctocog alfa, a manufacturing process using a well\u2010known mammalian cell line suitable for rFVIII production and entirely free from added animal\u2010 or human\u2010derived additives was designed and developed. Three complementary approaches were used to minimize the risk of potential contamination: thorough testing of cell lines and close control of medium, the capacity of the purification process to eliminate potential contaminations and systematic analysis of the final product. The safety data obtained to date demonstrate that Turoctocog alfa can be safely used in the clinical practice and that the manufacturing process sets new standards in terms of purity and pathogen safety.",
            "cite_spans": [],
            "section": "Conclusions",
            "ref_spans": []
        },
        {
            "text": "The Author declares that he served as consultant for Novo Nordisk A/S, CSL Behring and Pfizer and received a grant for research from Baxter and from Bayer.",
            "cite_spans": [],
            "section": "Conflicts of interest disclosure",
            "ref_spans": []
        }
    ],
    "ref_entries": {
        "TABREF0": {
            "text": "Table 1: Emerging infectious disease agents associated with potential blood, plasma or FVIII concentrate transmission 39, 42, 43, 44, 45, 46, 47, 48, 49\n\n",
            "type": "table"
        },
        "TABREF1": {
            "text": "Table 2: Purification steps of Turoctocog alfa\n",
            "type": "table"
        }
    },
    "back_matter": [],
    "bib_entries": {
        "BIBREF0": {
            "title": "Activation of factor VIII and mechanisms of cofactor action",
            "authors": [],
            "year": 2004,
            "venue": "Blood Rev",
            "volume": "18",
            "issn": "",
            "pages": "1-15",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF1": {
            "title": "Molecular approaches for improved clotting factors for haemophilia",
            "authors": [],
            "year": 2013,
            "venue": "Hematology Am Soc Hematol Educ Program",
            "volume": "2013",
            "issn": "",
            "pages": "30-6",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF2": {
            "title": "Haemorrhagic diathesis: successful transfusion of blood",
            "authors": [],
            "year": 1840,
            "venue": "Lancet",
            "volume": "41",
            "issn": "",
            "pages": "185-8",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF3": {
            "title": "An adventure in biotechnology: the development of haemophilia A therapeutics \u2013 from whole\u2010blood transfusion to recombinant DNA to gene therapy",
            "authors": [],
            "year": 2002,
            "venue": "Biotechnol Appl Biochem",
            "volume": "35",
            "issn": "Pt 2",
            "pages": "141-8",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF4": {
            "title": "Mortality rates, life expectancy, and causes of death in people with hemophilia A or B in the United Kingdom who were not infected with HIV",
            "authors": [],
            "year": 2007,
            "venue": "Blood",
            "volume": "110",
            "issn": "",
            "pages": "815-25",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF5": {
            "title": "Effects of HIV infection on age and cause of death for persons with hemophilia A in the United States",
            "authors": [],
            "year": 2001,
            "venue": "Am J Hematol",
            "volume": "66",
            "issn": "",
            "pages": "229-40",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF6": {
            "title": "AIDS in the transfusion recipient",
            "authors": [],
            "year": 1991,
            "venue": "Pediatr Clin North Am",
            "volume": "38",
            "issn": "",
            "pages": "121-31",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF7": {
            "title": "Hemophilia therapy and blood\u2010borne pathogen risk",
            "authors": [],
            "year": 2006,
            "venue": "Semin Thromb Hemost",
            "volume": "32",
            "issn": "Suppl 2",
            "pages": "3-9",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF8": {
            "title": "The hemophilia's and their clinical management",
            "authors": [],
            "year": 2013,
            "venue": "Hematology Am Soc Hematol Educ Program",
            "volume": "2013",
            "issn": "",
            "pages": "261-7",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF9": {
            "title": "The incidence of factor VIII and factor IX inhibitors in the hemophilia population of the UK and their effect on subsequent mortality, 1977\u201099",
            "authors": [],
            "year": 2004,
            "venue": "J Thromb Haemost",
            "volume": "2",
            "issn": "",
            "pages": "1047-54",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF10": {
            "title": "Non\u2010fatal cardiovascular disease, malignancies, and other co\u2010morbidity in adult haemophilia patients",
            "authors": [],
            "year": 2012,
            "venue": "Thromb Res",
            "volume": "130",
            "issn": "",
            "pages": "157-62",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF11": {
            "title": "Recent advances in the development of coagulation factors and BN procoagulants for the treatment of hemophilia",
            "authors": [],
            "year": 2011,
            "venue": "Biochem Pharmacol",
            "volume": "82",
            "issn": "",
            "pages": "91-8",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF12": {
            "title": "Venous access in hemophilic children: choice and management",
            "authors": [],
            "year": 2010,
            "venue": "Haemophilia",
            "volume": "16",
            "issn": "Suppl 1",
            "pages": "20-4",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF13": {
            "title": "Blood clotting factor VIII: from evolution to therapy",
            "authors": [],
            "year": 2013,
            "venue": "Acta Naturae",
            "volume": "5",
            "issn": "",
            "pages": "19-39",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF14": {
            "title": "Recombinant therapeutic proteins: production platforms and challenges",
            "authors": [],
            "year": 2008,
            "venue": "Biotechnol J",
            "volume": "3",
            "issn": "",
            "pages": "90-7",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF15": {
            "title": "Coagulation factor concentrates: past, present, and future",
            "authors": [],
            "year": 2007,
            "venue": "Lancet",
            "volume": "370",
            "issn": "",
            "pages": "439-48",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF16": {
            "title": "Novel coagulation factor concentrates: issues relating to their clinical implementation and pharmacokinetic assessment for optimal prophylaxis in haemophilia patients",
            "authors": [],
            "year": 2013,
            "venue": "Haemophilia",
            "volume": "19",
            "issn": "",
            "pages": "481-6",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF17": {
            "title": "Bioequivalence between two serum\u2010free recombinant factor VIII preparations (N8 and ADVATE\u00ae)\u2013an open\u2010label, sequential dosing pharmacokinetic study in patients with severe haemophilia A",
            "authors": [],
            "year": 2011,
            "venue": "Haemophilia",
            "volume": "17",
            "issn": "",
            "pages": "854-9",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF18": {
            "title": "Effect of route of administration of human recombinant factor VIII on its immunogenicity in Hemophilia A mice",
            "authors": [],
            "year": 2009,
            "venue": "J Pharm Sci",
            "volume": "98",
            "issn": "",
            "pages": "4480-4",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF19": {
            "title": "Post\u2010production protein stability: trouble beyond the cell factory",
            "authors": [],
            "year": 2011,
            "venue": "Microb Cell Fact",
            "volume": "10",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF20": {
            "title": "Characterisation of the post\u2010translational modifications of a novel, human cell line\u2010derived recombinant human factor VIII",
            "authors": [],
            "year": 2013,
            "venue": "Thromb Res",
            "volume": "131",
            "issn": "",
            "pages": "78-88",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF21": {
            "title": "Recombinant human albumin supports single cell cloning of CHO cells in chemically defined media",
            "authors": [],
            "year": 2012,
            "venue": "Biotechnol Prog",
            "volume": "28",
            "issn": "",
            "pages": "887-91",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF22": {
            "title": "CHO cells in biotechnology for production of recombinant proteins: current state and further potential",
            "authors": [],
            "year": 2012,
            "venue": "Appl Microbiol Biotechnol",
            "volume": "93",
            "issn": "",
            "pages": "917-30",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF23": {
            "title": "Purification and characterization of a new recombinant factor VIII (N8)",
            "authors": [],
            "year": 2010,
            "venue": "Hemophilia",
            "volume": "16",
            "issn": "",
            "pages": "349-59",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF24": {
            "title": "Factor VIII inhibitors in mild and moderate\u2010severity haemophilia A",
            "authors": [],
            "year": 1998,
            "venue": "Haemophilia",
            "volume": "4",
            "issn": "",
            "pages": "558-63",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF25": {
            "title": "VWF protects FVIII from endocytosis by dendritic cells and subsequent presentation to immune effectors",
            "authors": [],
            "year": 2007,
            "venue": "Blood",
            "volume": "109",
            "issn": "",
            "pages": "610-2",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF26": {
            "title": "Multiple changes in sialic acid biology during human evolution",
            "authors": [],
            "year": 2009,
            "venue": "Glycoconj J",
            "volume": "26",
            "issn": "",
            "pages": "231-45",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF27": {
            "title": "Sensitive and specific detection of the non\u2010human sialic Acid N\u2010glycolylneuraminic acid in human tissues and biotherapeutic products",
            "authors": [],
            "year": 2009,
            "venue": "PLoS ONE",
            "volume": "4",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF28": {
            "title": "Charge analysis of N\u2010glycans from human recombinant coagulation factor VIII and human FVIII standards",
            "authors": [],
            "year": 2004,
            "venue": "Thromb Haemost",
            "volume": "92",
            "issn": "",
            "pages": "427-8",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF29": {
            "title": "Factor VIII products and inhibitor development in severe hemophilia A",
            "authors": [],
            "year": 2013,
            "venue": "N Engl J Med",
            "volume": "368",
            "issn": "",
            "pages": "231-9",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF30": {
            "title": "Recent advances in technology supporting biopharmaceutical production from mammalian cells",
            "authors": [],
            "year": 2012,
            "venue": "Appl Microbiol Biotechnol",
            "volume": "96",
            "issn": "",
            "pages": "885-94",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF31": {
            "title": "Standardization of factor VIII and von Willebrand factor in plasma: calibration of the WHO 5th International Standard (02/150)",
            "authors": [],
            "year": 2004,
            "venue": "J Thromb Haemost",
            "volume": "2",
            "issn": "",
            "pages": "1380-4",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF32": {
            "title": "",
            "authors": [],
            "year": 1985,
            "venue": "Animal Cell Biotechnology",
            "volume": "",
            "issn": "",
            "pages": "85-122",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF33": {
            "title": "Cell engineering and cultivation of Chinese hamster ovary (CHO) cells",
            "authors": [],
            "year": 2010,
            "venue": "Curr Pharm Biotechnol",
            "volume": "11",
            "issn": "",
            "pages": "233-40",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF34": {
            "title": "Functional characteristics of N8, a new recombinant FVIII",
            "authors": [],
            "year": 2010,
            "venue": "Haemophilia",
            "volume": "16",
            "issn": "",
            "pages": "878-87",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF35": {
            "title": "A multicenter pharmacosurveillance study for the evaluation of the efficacy and safety of recombinant factor VIII in the treatment of patients with hemophilia A. German Kogenate Study Group",
            "authors": [],
            "year": 1997,
            "venue": "Thromb Haemost",
            "volume": "78",
            "issn": "",
            "pages": "1352-6",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF36": {
            "title": "The use of solvent/detergent treatment in pathogen reduction of plasma",
            "authors": [],
            "year": 2011,
            "venue": "Transfus Med Hemother",
            "volume": "38",
            "issn": "",
            "pages": "65-70",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF37": {
            "title": "Gamma irradiation of animal sera for inactivation of viruses and mollicutes \u2013 a review",
            "authors": [],
            "year": 2011,
            "venue": "Biologicals",
            "volume": "39",
            "issn": "",
            "pages": "370-7",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF38": {
            "title": "Virologic and clinical features of primary infection with human parvovirus 4 in subjects with hemophilia: frequent transmission by virally inactivated clotting factor concentrates",
            "authors": [],
            "year": 2012,
            "venue": "Transfusion",
            "volume": "52",
            "issn": "",
            "pages": "1482-9",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF39": {
            "title": "Clinical perspectives of emerging pathogens in bleeding disorders",
            "authors": [],
            "year": 2006,
            "venue": "Lancet",
            "volume": "367",
            "issn": "",
            "pages": "252-61",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF40": {
            "title": "Emerging infectious agents and the nation's blood supply: responding to potential threats in the 21st century",
            "authors": [],
            "year": 2013,
            "venue": "Transfusion",
            "volume": "53",
            "issn": "",
            "pages": "438-54",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF41": {
            "title": "Variant CJD infection in the spleen of a neurologically asymptomatic UK adult patient with haemophilia",
            "authors": [],
            "year": 2010,
            "venue": "Haemophilia",
            "volume": "16",
            "issn": "",
            "pages": "296-304",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF42": {
            "title": "Dealing with the uncertain risk of variant Creutzfeldt\u2010Jakob disease transmission by coagulation replacement products",
            "authors": [],
            "year": 2012,
            "venue": "Br J Haematol",
            "volume": "158",
            "issn": "",
            "pages": "442-52",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF43": {
            "title": "Prion diseases are efficiently transmitted by blood transfusion in sheep",
            "authors": [],
            "year": 2008,
            "venue": "Blood",
            "volume": "112",
            "issn": "",
            "pages": "4739-45",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF44": {
            "title": "Molecular pathology, classification, and diagnosis of sporadic human prion disease variants",
            "authors": [],
            "year": 2012,
            "venue": "Folia Neuropathol",
            "volume": "50",
            "issn": "",
            "pages": "20-45",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF45": {
            "title": "Evidence for the transmission of parvovirus B19 in patients with bleeding disorders treated with plasma\u2010derived factor concentrates in the era of nucleic acid test screening",
            "authors": [],
            "year": 2013,
            "venue": "Transfusion",
            "volume": "53",
            "issn": "",
            "pages": "1217-25",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF46": {
            "title": "Human herpesvirus 8 infection in haemophiliacs",
            "authors": [],
            "year": 2000,
            "venue": "Thromb Haemost",
            "volume": "84",
            "issn": "",
            "pages": "515-7",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF47": {
            "title": "Prevalence of Kaposi's sarcoma\u2010associated herpesvirus infection in haemophilic patients",
            "authors": [],
            "year": 2003,
            "venue": "Haemophilia",
            "volume": "9",
            "issn": "",
            "pages": "657-9",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF48": {
            "title": "TT virus contaminates first\u2010generation recombinant factor VIII concentrates",
            "authors": [],
            "year": 2001,
            "venue": "Blood",
            "volume": "98",
            "issn": "",
            "pages": "2571-3",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF49": {
            "title": "Emerging trends in plasma\u2010free manufacturing of recombinant protein therapeutics expressed in mammalian cells",
            "authors": [],
            "year": 2009,
            "venue": "Biotechnol J",
            "volume": "4",
            "issn": "",
            "pages": "186-201",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF50": {
            "title": "The most infectious prion protein particles",
            "authors": [],
            "year": 2005,
            "venue": "Nature",
            "volume": "437",
            "issn": "",
            "pages": "257-61",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF51": {
            "title": "Prevalent abnormal prion protein in human appendixes after bovine spongiform encephalopathy epizootic: large scale survey",
            "authors": [],
            "year": 2013,
            "venue": "BMJ",
            "volume": "347",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF52": {
            "title": "Facilitated cross\u2010species transmission of prions in extraneural tissue",
            "authors": [],
            "year": 2012,
            "venue": "Science",
            "volume": "335",
            "issn": "",
            "pages": "472-5",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF53": {
            "title": "Update on pathogen reduction technology for therapeutic plasma: an overview",
            "authors": [],
            "year": 2006,
            "venue": "Transfus Apher Sci",
            "volume": "35",
            "issn": "",
            "pages": "83-90",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF54": {
            "title": "Nanofiltration of plasma\u2010derived biopharmaceutical products",
            "authors": [],
            "year": 2003,
            "venue": "Haemophilia",
            "volume": "9",
            "issn": "",
            "pages": "24-37",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF55": {
            "title": "Implementation of a 20\u2010nm pore\u2010size filter in the plasma\u2010derived factor VIII manufacturing process",
            "authors": [],
            "year": 2006,
            "venue": "Vox Sang",
            "volume": "91",
            "issn": "",
            "pages": "119-25",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF56": {
            "title": "Virus separation using membranes",
            "authors": [],
            "year": 2014,
            "venue": "Methods Mol Biol",
            "volume": "1104",
            "issn": "",
            "pages": "459-91",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF57": {
            "title": "Membrane\u2010based techniques for the separation and purification of proteins: an overview",
            "authors": [],
            "year": 2009,
            "venue": "Adv Colloid Interface Sci",
            "volume": "145",
            "issn": "",
            "pages": "1-22",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF58": {
            "title": "Hemophilia A in the third millennium",
            "authors": [],
            "year": 2013,
            "venue": "Blood Rev",
            "volume": "27",
            "issn": "",
            "pages": "179-84",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF59": {
            "title": "Results from a large multinational clinical trial (guardian\u21221) using prophylactic treatment with turoctocog alfa in adolescent and adult patients with severe haemophilia A: safety and efficacy",
            "authors": [],
            "year": 2013,
            "venue": "Haemophilia",
            "volume": "19",
            "issn": "",
            "pages": "691-7",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF60": {
            "title": "Results from a large multinational clinical trial (guardian\u21223) using prophylactic treatment with turoctocog alfa in paediatric patients with severe hemophilia A: safety, efficacy and pharmacokinetics",
            "authors": [],
            "year": 2013,
            "venue": "Haemophilia",
            "volume": "19",
            "issn": "",
            "pages": "698-705",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF61": {
            "title": "Future of coagulation factor replacement therapy",
            "authors": [],
            "year": 2013,
            "venue": "J Thromb Haemost",
            "volume": "11",
            "issn": "Suppl 1",
            "pages": "84-98",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF62": {
            "title": "Pharmacokinetics and pharmacodynamics of turoctocog alfa and N8\u2010GPin hemophilia A dogs",
            "authors": [],
            "year": 2012,
            "venue": "Haemophilia",
            "volume": "18",
            "issn": "",
            "pages": "941-7",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF63": {
            "title": "A novel B\u2010domainO\u2010glycoPEGylated FVIII (N8\u2010GP) demonstrates full efficacy and prolonged effect in hemophilic mice models",
            "authors": [],
            "year": 2013,
            "venue": "Blood",
            "volume": "121",
            "issn": "",
            "pages": "2108-16",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF64": {
            "title": "Enhancing the pharmacokinetic properties of recombinant factor VIII: first\u2010in\u2010human trial of glycoPEGylated recombinant factor VIII in patients with hemophilia A",
            "authors": [],
            "year": 2013,
            "venue": "J Thromb Haemost",
            "volume": "11",
            "issn": "",
            "pages": "670-8",
            "other_ids": {
                "DOI": []
            }
        }
    }
}